NCT01063023

Drug Interaction Oral Contraceptive Pill (OCP)

Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects

Conditions

• Hepatitis C Virus

Interventions

Type	Name	Description
DRUG	Ortho Tri-Cyclen®	Tablets, Oral, 1 Tablet, once daily
DRUG	BMS-650032	Tablets, Oral, 600 mg, BID

Timeline

• Start date: 2010-01-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2010-02-05
• Last updated: 2011-01-25

Locations

1 site across 1 country: United States